In recent years, digital pathology adoption has exploded, offering an array of potential advantages for clinical trials, including enhanced workflow efficiency and new opportunities for collaboration and clinical insights. Complex global logistics and a lack of standardized processes have limited the effectiveness of digital pathology in clinical trials until only recently.
Find out how Q Squared Solutions is centralizing clinical trials and clinical development on an enterprise platform to deliver global access to more patients, laboratories, and pathology leaders, enabling them to streamline trials and maximize trial success.
You’ll walk away from this discussion with a valuable perspective on:
- Ability of digital pathology to shave weeks or months off trials through logistics automation, immediate expert access, and reduced study overhead
- How digitization can drive standardization and reproducibility in clinical development
- Opportunities for extracting deeper insight across the R&D life cycle with an enterprise pathology approach
Presenters
John Cochran, MD, FCAP
Chief Medical Officer and Chief Pathologist
Q Squared Solutions
Amanda Hemmerich, MD
Director of Digital Pathology Innovation
Q Squared Solutions
Nathan Buchbinder
Chief Strategy Officer
Proscia
About Pathology at Life Speed
Pathology at Life Speed is a webinar series featuring speakers and topics designed to help biopharma companies, biotechs, CROs, academic research centers and commercial laboratories to unlock the full potential of pathology and precision medicine. Learn how new technologies and innovations in pathology can accelerate R&D, and help labs stay ahead of the pace of the market. The PALS webinar series will explore how:
- Data & AI are rewiring how we discover, develop, and bring to patients life-saving treatments.
- Breakthroughs in biology are transforming patient care, with precision therapies in oncology and beyond.
- Digital pathology, spatial biology, and AI offer new tools to deepen our understanding of disease at a tissue, cellular, and molecular level, and ensure the right patients get on the right drugs.
SOURCE: Proscia
